Specifically, recent epidemiological studies have linked a high plasma level of the phosphaturic hormone fibroblast growth factor 23 (FGF23) with an increased risk of cardiovascular disease in CKD patients [8,9,10,11]. Here, FGF23 is linked to cardiovascular disorder.